Abbott Laboratories Analyst Ratings
Redburn Adjusts Price Target on Abbott Laboratories to $113 From $115
Abbott Laboratories Analyst Ratings
Optimistic Buy Rating for Abbott Laboratories on Diverse Portfolio and Growth Prospects
Critical Insights From Abbott Laboratories Analyst Ratings: What You Need To Know
Abbott Laboratories Analyst Ratings
Citigroup Adjusts Price Target on Abbott Laboratories to $119 From $128, Keeps Buy Rating
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Immunocore Holdings (IMCR) and Madrigal Pharmaceuticals (MDGL)
Analysts Conflicted on These Healthcare Names: Abbott Laboratories (ABT), PolyPid (PYPD) and GoodRx Holdings (GDRX)
Buy Rating Affirmed for Abbott Laboratories Based on Strong EP Business and Strategic Growth Prospects
RBC Capital Keeps Their Buy Rating on Abbott Laboratories (ABT)
Abbott Laboratories Analyst Ratings
Abbott Laboratories Analyst Ratings
Abbott Laboratories Analyst Ratings
Abbott Laboratories Analyst Ratings
Abbott Laboratories Analyst Ratings
Edwards Stock Jumps 8% on FDA Approval, Wells Fargo Upgrade
Abbott Laboratories Analyst Ratings
JPMorgan Raises Abbott Laboratories Price Target to $125 From $122, Maintains Overweight Rating
RBC Capital Sticks to Its Buy Rating for Abbott Labs (ABT)